ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Erratum issuedAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Biocompatible ligand balancing in transition metal coordination enables benign in-cell protein arylation.Nature chemistry · 2026Article
- MAP4 phosphorylation induced by ARID1A loss sensitizes colorectal cancer cells to EMP.Cell death & disease · 2025Article
- ARIH1 Inhibition Promotes Microtubule Stability and Sensitizes Breast Cancer Cells to Microtubule-Stabilizing Agents.Cancers · 2025Article
- cGAS/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values.Frontiers in immunology · 2025Review
- Cancer nuclear envelope rupture and repair in taxane resistance.Medical review (2021) · 2024Review
- RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells.bioRxiv : the preprint server for biology · 2024Article
- Review
- MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.Journal of cancer research and clinical oncology · 2024Article
- CENPN suppresses autophagy and increases paclitaxel resistance in nasopharyngeal carcinoma cells by inhibiting the CREB-VAMP8 signaling axis.Autophagy · 2024Article
- CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling.European journal of medical research · 2023Article
- Regulation of Cell Adhesion and Migration via Microtubule Cytoskeleton Organization, Cell Polarity, and Phosphoinositide Signaling.Biomolecules · 2023Review
- Drivers of plateau adaptability in cashmere goats revealed by genomic and transcriptomic analyses.BMC genomics · 2023Article
- Knockdown of STK39 suppressed cell proliferation, migration, and invasion in hepatocellular carcinoma by repressing the phosphorylation of mitogen-activated protein kinase p38.Bioengineered · 2021Article
- Article
- Article
- Spike-in normalization for single-cell RNA-seq reveals dynamic global transcriptional activity mediating anticancer drug response.NAR genomics and bioinformatics · 2021Article
- STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.Theranostics · 2021Article
- Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients.Frontiers in oncology · 2021Article
- Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer.Cancers · 2020Article
- Mechanisms of Taxane ResistanceCancers · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 2 institutions in 2 countries.
Hailing YangDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Weiqun MaoDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Lingegowda S MangalaCenter for RNA Interference and Non-Coding RNA, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Geoffrey BartholomeuszDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Lakesla R IlesDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Nicholas B JenningsCenter for RNA Interference and Non-Coding RNA, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Ahmed Ashour AhmedOvarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford, United Kingdom.
Anil K SoodCenter for RNA Interference and Non-Coding RNA, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Zhen LuDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Robert C BastDepartment of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, Houston, Texas. rbast@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USJohn Radcliffe Hospital · GB
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MU.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9MHarnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA217685NCI NIH HHS R35 CA209904
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic Agents, PhytogenicApoptosisBiomarkersCell CycleCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesGenes, BRCA1Genes, BRCA2Genes, p53HumansMiceMicrotubule-Associated ProteinsAntineoplastic Agents, PhytogenicBiomarkersMAP4 protein, humanMicrotubule-Associated Proteinsp38 Mitogen-Activated Protein KinasesPaclitaxelProtein KinasesRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.